Abstract: A method and device for acquiring a rotor position based on a permanent magnet synchronous drive system. The permanent magnet synchronous drive system includes an inverter and a permanent magnet synchronous motor, wherein the initial speed of the permanent magnet synchronous motor is not zero. The method includes: controlling a bridge arm switch of an inverter periodically; collecting a three-phase current of the permanent magnet synchronous motor at a fixed time within each control period; and after the three-phase current is reversed, sending same to a phase-locked loop system to conduct processing, so as to obtain a phase angle of an induction potential vector, and according to the phase angle of the induction potential vector, acquiring a rotor position angle of the permanent magnet synchronous motor.

Abstract: A control method for restarting a permanent magnet synchronous motor (PMSM) in a rotating condition, and a device and a system thereof are provided. In the method, an electrical angular speed ?e of the PMSM is obtained based on a speed of a trailer to obtain a back electromotive force of the PMSM. The back electromotive force is compared with a voltage at a side of an inverter, and if the electromotive force of the permanent magnet synchronous motor is higher than the voltage at the side of the inverter, the restarting of the PMSM is forbidden, otherwise, the restarting of the PMSM is allowed. Therefore, in the present disclosure, the low-speed operating condition and the high-speed operating condition correspond to different position angles of the rotor, and the PMSM is started based on the position angle of the rotor.

Abstract: A direct-axis current protection method and device for a permanent magnet synchronous motor drive system. The method includes: pre-calculating the direct-axis current of the next moment according to the current voltage transmitted from an inverter to a permanent magnet synchronous motor (PMSM); comparing the direct-axis current of the next moment with a maximum protection current; if the direct-axis current of the next moment is less than the maximum protection current, continuing transmitting the current voltage to the PMSM; if the direct axis current of the next moment is greater than or equal to the maximum protection current, redistributing the voltage according to a protection direct-axis current and a protection quadrature-axis current, and transmitting the redistributed voltage to the PMSM. The direct-axis current of the next moment is tended to be normal by adjusting the voltage.

Abstract: The present disclosure provides methods and pharmaceutical compositions for treating depigmentation diseases such as vitiligo or leukoctricia. The pharmaceutical composition contains a therapeutically effective amount of fluoxetine.

Abstract: Disclosed in the present invention are a bis-?-carboline compound and a preparation method, a pharmaceutical composition and the use thereof. In particular, the bis-?-carboline compound and a pharmaceutical salt thereof are described as general formula I, and the bis-?-carboline compound is prepared through the condensation of ?-carboline intermediate and dihaloalkane. Also disclosed in the present invention are a pharmaceutical composition comprising an effective dose of the bis-?-carboline compound as shown in formula I and a pharmaceutically acceptable carrier, and the use of the bis-?-carboline compound in preparing drugs resistant to tumours such as melanoma, stomach cancer, lung cancer, breast cancer, kidney cancer, liver cancer, oral epidermoid carcinoma, cervical cancer, ovarian cancer, pancreatic cancer, prostate cancer, and colon cancer.

Abstract: The present invention relates to the field of medicine and particularly relates to the application of fluoxetine to the treatment of depigmentation diseases. Pharmacodynamic tests have demonstrated that fluoxetine has the effects of treating depigmentation diseases especially leukotrichia and vitiligo.

Abstract: An integrated security switch and related method for managing connectivity and security among networks. The integrated security switch includes a security function connectable with a first network and at least one switching function connectable with a second network. A common management interface driven by both command line interface and graphic user interface protocols manages the switching function via a management path dedicated between the security function and the switching function. The common management interface enables secure switching of traffic to flow via a traffic path dedicated between the switching function and the security function. Typically, the traffic is a flow of data between the Internet and a group of networked users such as a wide area network.

Abstract: An integrated security switch and related method for managing connectivity and security among networks. The integrated security switch includes a security function connectable with a first network and at least one switching function connectable with a second network. A common management interface driven by both command line interface and graphic user interface protocols manages the switching function via a management path dedicated between the security function and the switching function. The common management interface enables secure switching of traffic to flow via a traffic path dedicated between the switching function and the security function. Typically, the traffic is a flow of data between the Internet and a group of networked users such as a wide area network.

Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.

Abstract: The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.